Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own2.30% Shs Outstand342.40M Perf Week1.61%
Market Cap9.49B Forward P/E3.60 EPS next Y7.71 Insider Trans2.74% Shs Float332.43M Perf Month-9.23%
Income-988.40M PEG- EPS next Q1.78 Inst Own66.80% Short Float7.84% Perf Quarter36.75%
Sales10.32B P/S0.92 EPS this Y-133.00% Inst Trans20.59% Short Ratio1.00 Perf Half Y-3.95%
Book/sh15.35 P/B1.81 EPS next Y17.90% ROA-2.00% Target Price44.39 Perf Year-86.77%
Cash/sh2.49 P/C11.13 EPS next 5Y11.07% ROE-17.00% 52W Range18.55 - 225.54 Perf YTD-72.73%
Dividend- P/FCF7.29 EPS past 5Y4.40% ROI3.70% 52W High-87.71% Beta-0.15
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin74.70% 52W Low49.43% ATR1.27
Employees22000 Current Ratio1.40 Sales Q/Q-50.60% Oper. Margin7.70% RSI (14)50.54 Volatility3.49% 3.82%
OptionableYes Debt/Eq5.87 EPS Q/Q-780.40% Profit Margin-9.60% Rel Volume0.47 Prev Close26.85
ShortableYes LT Debt/Eq5.81 EarningsAug 09 BMO Payout- Avg Volume25.95M Price27.72
Recom2.90 SMA20-3.16% SMA504.82% SMA200-42.27% Volume12,081,313 Change3.24%
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Mar-16-16Reiterated Canaccord Genuity Hold $75 → $40
Mar-16-16Downgrade Nomura Buy → Neutral $175 → $60
Sep-25-16 10:00AM  Wealth Preservation: "All I Know Is That I Know Nothing" at Investopedia
Sep-23-16 05:25PM  Investing for the Next 100 Years at
04:46PM  Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
04:11PM  Is Valeant Pharmaceuticals Playing With Fire? at Motley Fool
03:21PM  Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
02:23PM  Pharma ETF Looks Healthy in a Sick Market After Endo Names New CEO
01:11PM  Endo Int'l: New CEO "Has His Work Cut Out For Him" at
12:18PM  Valeant Needs Time If It Is to Recover and Rise
Sep-22-16 02:38PM  [$$] SEC's pursuit of Leon Cooperman rattles hedge fund industry at Financial Times
11:04AM  Jim Chanos Is Still Short on Valeant, Bill Miller Is Positive
Sep-21-16 06:49PM  [$$] Mylan chief comes under fire over cost of EpiPen at Financial Times
12:16PM  Valeant (VRX) Stock Higher on Potential $1 Billion iNova Sale
08:04AM  What Is the Upside Potential for Valeant?
Sep-20-16 01:30PM  Valeant's $1.5 Billion 'Capital Hole' -- and $31 Billion in Debt
12:07PM  Five Canadian Stocks Hedge Funds Like at Insider Monkey
11:42AM  Valeant Pharmaceuticals: Remember Them? at
11:30AM  Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'
11:27AM  Valeant (VRX) Stock Receives 'Hold' Rating at Deutsche Bank
11:04AM  How Will Valeants Profitability Pan Out over the Long Term?
10:04AM  Why Valeant Offers Volume-Based Discounts for These Drugs
08:04AM  Valeants Strategies for Its Dermatology, Gastroenterology Drugs
Sep-19-16 04:04PM  How Valeant Plans to Its Fix Dermatology Portfolio
03:56PM  Hateful Paper: Washed Out, Worth A Shot at Forbes
03:04PM  Projected Revenue for Valeant in 2017
12:59PM  Understanding Valeants Improved Valuation Multiple
11:22AM  Valeant has started taking a huge risk
09:07AM  Valeant Keeps Raising Drug Prices, Stock Still Carries Too Much Risk: Wells Fargo
08:27AM  [$$] Serial acquirers: fools not suffered at Financial Times
07:00AM  From a wrist slap to jail time: how the SEC deals with dodgy accounting at MarketWatch
06:00AM  Trump Means Change Equals Major Inflection Point
Sep-18-16 07:00AM  Is It Time to Get Small? at Morningstar
Sep-16-16 05:25PM  Valeant says discount program for heart drugs on track Reuters
04:25PM  Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel PR Newswire
04:25PM  Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel CNW Group
03:13PM  Hospitals say Valeant may be blowing off the government more than we thought
11:04AM  Why Does Bill Miller Like Valeant Pharmaceuticals?
05:00AM  Valeant Drug Discounts Havent Materialized, Hospitals Say at Bloomberg
Sep-15-16 03:29PM  The Single Most Important Metric to Determine if Valeant Pharmaceuticals Is a Buy at Motley Fool
Sep-14-16 02:11PM  Guggenheim Analyst Chen Takes Bullish Outlook On Valeant's (VRX) Growth Potential
11:29AM  Delivering Alpha -- and Animosity: Conference Speakers Agree on Little
Sep-13-16 07:01PM  Cramer: We Need to Be Able to Predict a Clear Election Winner
04:35PM  Bill Miller: Valeant shares could post 25-30 pct returns over 5 years Reuters
02:02PM  Top Stock Picks From CNBC's Delivering Alpha Conference
01:59PM  Jim Chanos: I'm still short Valeant and not about to quit at CNBC
10:12AM  Valeant Pharmaceuticals (VRX) Stock Down, CEO Papa Mulls Asset Sales
Sep-12-16 04:35PM  2 Things Ackman Wants to Change at Chipotle
04:25PM  Perrigo Jumps As Starboard Reveals Big Stake, Demands Changes
01:44PM  [$$] Perrigo shares jump as activist Starboard's stake revealed at Financial Times
12:58PM  Valeant's CEO was clueless when analysts asked about a specialty pharmacy his company deals with
Sep-11-16 02:00PM  One year after it was approved, a look back on the 'female Viagra'
Sep-09-16 04:34PM  Teva Discusses EpiPen Comps as Host of Generics Unveiled -6.34%
02:54PM  Hillary Clinton's New Prescription Drug Proposal Takes Aim at Valeant Pharmaceuticals and Mylan at Motley Fool
10:02AM  Bill Ackmans Stances on Valeant Pharmaceuticals and Herbalife
Sep-08-16 10:10AM  The EpiPen isn't the only drug that's more than doubled in price
09:41AM  3 Reasons Behind Valeant Pharmaceuticals Intl. Inc.'s 30% Ascent in August at Motley Fool
Sep-07-16 07:04PM  Whats Been Helping PRITX Year-to-Date?
05:41PM  Valeant CEO says he'll never say never to selling core assets like Bausch & Lomb at CNBC
01:28PM  Zoetis Remains Attractive Alternative Healthcare Investment
01:14PM  [$$] Chipotle shares jump as Ackman builds 9.9% stake at Financial Times
12:40PM  Invest Where You Eat: Ackman's Love of Chipotle Burritos at The Wall Street Journal
10:20AM  Ackman's Pershing Square Bets on Chipotle (CMG, VRX) at Investopedia
09:17AM  Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
07:52AM  Chipotle May Further Franchise, Prep for Sale as Ackman Launches Campaign
Sep-06-16 06:31PM  Here's how Ackman's other bets are doing this year at CNBC
06:13PM  Chipotle Jumps Late On 9.9% Pershing Square Stake
05:00PM  Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets PR Newswire
05:00PM  Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets CNW Group
09:20AM  Allergan CEO: No More Predatory Drug Pricing
Sep-05-16 06:08AM  Stop Fighting the Tape
Sep-03-16 08:00AM  Is EpiPen's Price The FDA's Fault? What's Holding Up New Generics?
Sep-02-16 02:33PM  Clinton's New Drug-Price Plan Only a Good Start at Bloomberg
01:59PM  [$$] Clinton promises panel to vet drug price rises at Financial Times
11:24AM  Is Mylan The Next Valeant Trade? (MYL, VRX) at Investopedia
Sep-01-16 07:36PM  Ackman's Pershing Square Holdings gains 5.8 percent in August
Aug-31-16 03:49PM  If I Were a Valeant Pharmaceuticals Shareholder, This Would Infuriate Me at Motley Fool
01:38PM  Elizabeth Warren just demanded Mylan come clean about one of the biggest secrets in pharma
01:25PM  Chou RRSP Fund Buys Valeant
12:27PM  Bill Ackman's Cry: "Worst Period Of Performance" (HLN, VRX) at Investopedia
11:05AM  Will Xtandi Fuel Pfizers Top-Line Growth?
09:11AM  Orexigen Stock Up on Commercialization Deal for Contrave
Aug-30-16 05:00PM  Valeant Pharmaceuticals To Participate In September Healthcare Conferences PR Newswire
05:00PM  Valeant Pharmaceuticals To Participate In September Healthcare Conferences CNW Group
04:23PM  Whats behind Mallinckrodts Stratatech Acquisition?
01:49PM  Billionaire Showdown: Is Valeant Pharmaceuticals International Worth the Risk? at Motley Fool
11:30AM  Big Pharma's Punishment in Court of Public Opinion
09:31AM  Why Do Hedge Funds Like AMAG Pharmaceuticals? at Insider Monkey
09:30AM  Big Pharma Has No Rx for Viral Social Media Reactions
06:56AM  Valeant is being sued under racketeering law over drug price hikes at MarketWatch
Aug-29-16 11:40PM  Valeant International Sued For Alleged Racketeering (VRX) at Investopedia
05:41PM  Valeant is sued over Philidor ties, alleged racketeering
05:03PM  Healthcare Winners: Stryker Corp., UnitedHealth Group Inc.
03:58PM  Valeant (VRX) Stock Falls on Lawsuit
03:53PM  Valeant Being Sued In NY Federal Court Over Alleged Overcharges
01:07PM  Bill Ackman Comments on Valeant
11:30AM  EYEG: Posisitve Cataract Surgery Data, Initial CMHA-S Clinical Program
10:00AM  [$$] Mylan to launch cut-price generic version of EpiPen at Financial Times
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-27-16 12:30AM  [$$] Hong Kong Tribunal Rules Against U.S. Short-Seller Andrew Left at The Wall Street Journal
Aug-26-16 07:22PM  MOVES-Pershing Square's Valeant analyst to exit, Ackman sees stock rising
07:02PM  Bill Ackman Discusses Worst Year Ever in Mid-Year Letter
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM